This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

CIC Fact Sheet

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Forest Laboratories, Inc. (NYSE:FRX) announced today that they have commenced a new direct-to-consumer (DTC) patient awareness campaign for LINZESS® (linaclotide), a once-daily treatment for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). The campaign aims to help adults suffering from IBS-C or CIC recognize the symptoms of these disorders, describe their symptoms to their doctor, and ask their doctor about LINZESS to help proactively manage their disease. The television portion of the campaign premiered last night on ABC.

“Millions of adults suffer from IBS-C or CIC, but many have not been diagnosed. They may not realize that long-lasting or recurrent symptoms such as infrequent or difficult-to-pass stools, not completely emptying the bowels, and – in IBS-C – belly pain, could indicate the presence of a medical condition and warrant discussion with a doctor,” said Tom McCourt, chief commercial officer at Ironwood . “Even among patients who are diagnosed with IBS-C or CIC, fewer than 10 percent are aware of LINZESS, so we see a significant need to raise awareness of these disease states and of LINZESS as a possible treatment option.”

The consumer awareness campaign is based on research that revealed gaps in the dialogue when and if adult patients with IBS-C or CIC describe their symptoms to their doctor. The comprehensive campaign includes print advertisements in highly visible consumer magazines such as People, Cooking Light and Better Homes & Gardens; television advertising during several Top 10 programs including Modern Family, The Voice and NCIS; online advertising; an updated brand web site (; and brochures available in doctors’ offices and pharmacies.

“Forest has traditionally focused primarily on physician-facing activities rather than DTC, but with LINZESS, we felt we had a unique opportunity to reach patients who were having a difficult time identifying and conveying the symptoms they were experiencing,” said Bill Meury, executive vice president, sales and marketing at Forest. “We were struck by market research showing that many IBS-C and CIC sufferers don’t fully describe the severity, frequency, and recurring nature of their symptoms to their doctors, sometimes resulting in a misdiagnosis of common, occasional constipation. This campaign is intended to facilitate a more comprehensive conversation between adult patients and physicians, and to raise consumer awareness about these diseases and LINZESS as a treatment option.”

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs